All In Biotech

Drug Trial Radar · NCT05689853

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

An Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability and Antitumor Activity of AK119 in Combination With AK112 in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

87

Planned (sponsor's estimate)

Start

Apr 14, 2023

Primary completion

Dec 2026

Study completion Jun 2027

Sponsor

Lead sponsor
AkesoIndustry
Sponsor type
Industry
First posted
Jan 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase Ib/II study to assess the safety, tolerability and preliminary efficacy of AK119 combined with AK112 in patients with advanced solid tumors.

Conditions

  • Solid Tumor, Adult

Interventions

  • AK119Drug

    AK119 is an anti-CD73 monoclonal antibody.

  • AK112Drug

    AK112 is a bispecific monoclonal antibody against VEGF and PD-1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of subjects with dose limiting toxicities (DLTs)Time frame: During the first three weeks
  2. Number of subjects with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug.
  3. Objective Response Rate (ORR)Time frame: Up to 2 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.